PharmaZell, a German-based producer of speciality APIs, and France’s CDMO Groupe Novasep are to merge under the ownership of PharmaZell’s current majority shareholder, private equity firm Bridgepoint. This remains subject to consultation with employees and other closing conditions.
Inotiv, a US CRO specialising in nonclinical and analytical drug discovery and development services, has reached an agreement to acquire research models and services Envigo. The cash and shares deal gives UK-headquartered Envigo an enterprise value of about $545 million, and the combined company one of around $1.2 billion.
CEM and AmbioPharm, two firms based in the Carolinas, have formed a partnership for the production of GMP peptides for the pharmaceutical industry. Under this, AmbioPharm will have exclusive rights to use CEM’s large-scale microwave technology for solid-phase peptide synthesis (SPPS) at up to multi-kilogram quantities using proprietary scalable reactors.
CDMO Sterling Pharma Solutions has completed the initial phase of investment in its centre of excellence for research into the commercial applications of continuous flow chemistry at Dudley, UK. This follows the appointment in July of Professor Ian Baxendale of Durham University to head a dedicated team in this field.
Quotient Sciences is to invest £6.3 million to expand drug substance manufacturing at the site in Alnwick, UK, which it acquired along with Arcinova in February. This will also create 80 new jobs over the next three years and boost its capacity to develop complex medicines tenfold.
Eurazeo has announced that it has entered into exclusive discussions to sell its stake in French-based CDMO Seqens to funds advised by SK Capital Partners and its existing French shareholders, Mérieux Equity Partners.
Seqens commented that SK Capital’s involvement could enhance its position in the production of APIs, pharmaceutical intermediates and speciality ingredients. SK has already owned API manufacturer Wavelength Pharmaceuticals since 2017.
Curia has announced plans to invest about $35 million in order to expand commercial-scale API manufacturing capacity at its largest site in Rensselaer, New York, over the course of 18 months. This is the third significant announcement in the month since the former AMRI renamed itself.
